David R Owens1, Louise Traylor2, Marie-Paule Dain3, Wolfgang Landgraf4. 1. Institute of Life Sciences, Swansea University, Swansea, UK. Electronic address: OwensDR@cardiff.ac.uk. 2. Sanofi US, Inc., Bridgewater, NJ, USA. 3. Sanofi, Paris, France. 4. Sanofi, Frankfurt, Germany; Third Medical Department, University of Dresden, Germany.
Abstract
AIM: Evaluate early (0-12 weeks) and later (12-24 weeks) treatment outcomes in subjects with type 2 diabetes not achieving glycaemic control with oral antidiabetes drugs (OADs). METHODS: Selected data were pooled from 15 randomised, controlled treat-to-target (fasting plasma glucose < 100mg/dL [< 5.6 mmol/L]) trials adding insulin glargine to metformin, a sulphonylurea, or both. Glycaemic and hypoglycaemia parameters, insulin dose, and body weight at weeks 12 and 24 were assessed using individualised subject-level data. RESULTS: Data from 2837 subjects were analysed. HbA1c decreased from 8.8% (73 mmol/mol) at baseline by 1.4% (15 mmol/mol) at Week 12, and a further 0.2% (2 mmol/mol) at Week 24 in the pooled population. Similar reductions were observed across the different treatment groups. HbA1c < 7.0% (<53 mmol/mol) was reached by 34.8% of participants at Week 12 and an additional 24.3% by Week 24. Hypoglycaemia incidence and rates were similar during the early and continued treatment periods across all treatment combinations, but were markedly lower for insulin glargine plus metformin versus the other 2 regimens. CONCLUSIONS: Early and sustained glycaemic benefits with a low-risk of hypoglycaemia are observed after initiation of insulin glargine in a pooled type 2 diabetes cohort previously uncontrolled on OADs.
RCT Entities:
AIM: Evaluate early (0-12 weeks) and later (12-24 weeks) treatment outcomes in subjects with type 2 diabetes not achieving glycaemic control with oral antidiabetes drugs (OADs). METHODS: Selected data were pooled from 15 randomised, controlled treat-to-target (fasting plasma glucose < 100mg/dL [< 5.6 mmol/L]) trials adding insulinglargine to metformin, a sulphonylurea, or both. Glycaemic and hypoglycaemia parameters, insulin dose, and body weight at weeks 12 and 24 were assessed using individualised subject-level data. RESULTS: Data from 2837 subjects were analysed. HbA1c decreased from 8.8% (73 mmol/mol) at baseline by 1.4% (15 mmol/mol) at Week 12, and a further 0.2% (2 mmol/mol) at Week 24 in the pooled population. Similar reductions were observed across the different treatment groups. HbA1c < 7.0% (<53 mmol/mol) was reached by 34.8% of participants at Week 12 and an additional 24.3% by Week 24. Hypoglycaemia incidence and rates were similar during the early and continued treatment periods across all treatment combinations, but were markedly lower for insulinglargine plus metformin versus the other 2 regimens. CONCLUSIONS: Early and sustained glycaemic benefits with a low-risk of hypoglycaemia are observed after initiation of insulin glargine in a pooled type 2 diabetes cohort previously uncontrolled on OADs.
Authors: Anne L Peters; Milivoj Piletič; Johan Ejstrud; Karen Salvesen-Sykes; James Snyder; Keith Bowering Journal: Diabetes Obes Metab Date: 2019-04-23 Impact factor: 6.577
Authors: Alice Cheng; Stewart Harris; Francesco Giorgino; Jochen Seufert; Robert Ritzel; Kamlesh Khunti; Felipe Lauand; Lydie Melas-Melt; Jukka Westerbacka; Zsolt Bosnyak; Julio Rosenstock Journal: Diabetes Obes Metab Date: 2019-12-20 Impact factor: 6.577
Authors: Pablo Aschner; Juan J Gagliardino; Hasan Ilkova; Fernando Lavalle; Ambady Ramachandran; Jean Claude Mbanya; Marina Shestakova; Jean-Marc Chantelot; Juliana C N Chan Journal: Diabetologia Date: 2020-01-04 Impact factor: 10.122